A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat ® Inhaler

Condition:   Cystic Fibrosis Interventions:   Drug: BI 1265162;   Drug: Placebo Sponsor:   Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials